WORLD - The first recorded description of Polycystic Ovarian Syndrome, PCOS, was in 1935. Nearly a century later, this condition is now being renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS) after a 14-year global consensus process involving researchers, clinicians, patient advocates, and thousands of survey responses. The change was published in The Lancet in May 2026 and reflects a growing recognition that the old name did not fully capture the nature of the condition.
The issue was never only about language. The term “polycystic ovary syndrome” places too much emphasis on ovarian cysts, even though the condition is not limited to reproductive health. PMOS is now understood as a complex endocrine and metabolic condition that can affect weight, insulin resistance, skin, mental health, and long-term risks such as type 2 diabetes and cardiovascular disease.
This matters because PMOS affects a significant share of the global population. WHO estimates that PCOS affects around 10–13% of reproductive-aged women, while the new global consensus describes the condition as affecting one in eight women, or more than 170 million women worldwide.
But the name change also raises a broader question: why did it take nearly 100 years for one of the most common women’s health conditions to be named more accurately?
The answer points to a deeper gap in health systems: women’s health has too often been under-researched, underfunded, and misunderstood. According to the World Economic Forum, women and girls make up nearly half of the world’s population, yet women’s health has captured only 6% of private healthcare investment. The consequences are not only medical, but also social and economic. Women spend 25% more of their lives in poor health or with disability than men, amounting to an estimated 75 million years of healthy life lost globally.
Research funding tells a similar story. In 2020, only 5% of global health research and development funding was allocated to women’s health. Most of that went to women’s cancers, leaving only a very small share for other women-specific conditions, many of which are common, chronic, and deeply disruptive to quality of life.
This gap has shaped how diseases are studied, diagnosed, and treated. For decades, medical research and clinical trials have often treated the male body as the default model, leaving women more exposed to delayed diagnosis, adverse medication effects, and treatments that may not fully account for biological differences.
Conditions such as endometriosis, autoimmune disorders, menstrual health conditions, and PCOS have often been minimized, normalized, or wrongly framed as lifestyle, fertility, or psychological issues rather than serious health concerns requiring sustained research and care.
Stigma has made the problem worse. When symptoms are dismissed as “normal,” “emotional,” or “not urgent,” women are less likely to receive timely care, and health systems are less likely to prioritize research, funding, and specialized services.
Changing the name of PCOS to PMOS will not close the women’s health gap on its own. But it is a meaningful step. It acknowledges that women have waited too long for accurate language, better evidence, and more comprehensive care.
The larger challenge now is to ensure that this recognition translates into earlier diagnosis, better treatment, more research funding, and healthcare systems that no longer treat women’s pain and symptoms as secondary.
